Logo image of MGRX

MANGOCEUTICALS INC (MGRX) Stock Fundamental Analysis

NASDAQ:MGRX - Nasdaq - US56270V2051 - Common Stock - Currency: USD

2.08  +0.11 (+5.58%)

After market: 2.08 0 (0%)

Fundamental Rating

2

MGRX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 41 industry peers in the Consumer Staples Distribution & Retail industry. The financial health of MGRX is average, but there are quite some concerns on its profitability. MGRX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MGRX has reported negative net income.
In the past year MGRX has reported a negative cash flow from operations.
MGRX Yearly Net Income VS EBIT VS OCF VS FCFMGRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

The Return On Assets of MGRX (-51.38%) is worse than 95.12% of its industry peers.
MGRX has a Return On Equity of -55.20%. This is in the lower half of the industry: MGRX underperforms 78.05% of its industry peers.
Industry RankSector Rank
ROA -51.38%
ROE -55.2%
ROIC N/A
ROA(3y)-377.5%
ROA(5y)N/A
ROE(3y)-525.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MGRX Yearly ROA, ROE, ROICMGRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

1.3 Margins

Looking at the Gross Margin, with a value of 57.65%, MGRX belongs to the top of the industry, outperforming 95.12% of the companies in the same industry.
MGRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 57.65%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MGRX Yearly Profit, Operating, Gross MarginsMGRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 -5K -10K -15K -20K

More info and screens

5

2. Health

2.1 Basic Checks

MGRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MGRX has more shares outstanding
The debt/assets ratio for MGRX is higher compared to a year ago.
MGRX Yearly Shares OutstandingMGRX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 1M 2M 3M
MGRX Yearly Total Debt VS Total AssetsMGRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

An Altman-Z score of 5.75 indicates that MGRX is not in any danger for bankruptcy at the moment.
MGRX's Altman-Z score of 5.75 is amongst the best of the industry. MGRX outperforms 80.49% of its industry peers.
There is no outstanding debt for MGRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.75
ROIC/WACCN/A
WACC9%
MGRX Yearly LT Debt VS Equity VS FCFMGRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 5M -5M 10M

2.3 Liquidity

MGRX has a Current Ratio of 0.12. This is a bad value and indicates that MGRX is not financially healthy enough and could expect problems in meeting its short term obligations.
MGRX has a worse Current ratio (0.12) than 97.56% of its industry peers.
MGRX has a Quick Ratio of 0.12. This is a bad value and indicates that MGRX is not financially healthy enough and could expect problems in meeting its short term obligations.
MGRX has a worse Quick ratio (0.12) than 97.56% of its industry peers.
Industry RankSector Rank
Current Ratio 0.12
Quick Ratio 0.12
MGRX Yearly Current Assets VS Current LiabilitesMGRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 500K 1M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for MGRX have decreased strongly by -10.44% in the last year.
Looking at the last year, MGRX shows a very negative growth in Revenue. The Revenue has decreased by -39.50% in the last year.
EPS 1Y (TTM)-10.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.26%
Revenue 1Y (TTM)-39.5%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-48.95%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MGRX Yearly Revenue VS EstimatesMGRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 200K 400K 600K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MGRX. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MGRX Price Earnings VS Forward Price EarningsMGRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MGRX Per share dataMGRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

MGRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MANGOCEUTICALS INC

NASDAQ:MGRX (6/20/2025, 8:00:00 PM)

After market: 2.08 0 (0%)

2.08

+0.11 (+5.58%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupConsumer Staples Distribution & Retail
GICS IndustryConsumer Staples Distribution & Retail
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.68%
Inst Owner Change-8.92%
Ins Owners9.14%
Ins Owner Change16.92%
Market Cap22.94M
AnalystsN/A
Price TargetN/A
Short Float %2.73%
Short Ratio0.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 44.88
P/FCF N/A
P/OCF N/A
P/B 1.13
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.16
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.56
OCFYN/A
SpS0.05
BVpS1.84
TBVpS-0.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -51.38%
ROE -55.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 57.65%
FCFM N/A
ROA(3y)-377.5%
ROA(5y)N/A
ROE(3y)-525.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.12
Quick Ratio 0.12
Altman-Z 5.75
F-Score4
WACC9%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.26%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-39.5%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-48.95%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-23.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.49%
OCF growth 3YN/A
OCF growth 5YN/A